Market Analysis
published on Nov 13, 2019
Report Overview:
NelsonHall’s “Operational Transformation in the Pharmaceuticals Sector: 2019” 40-page report is based on global interviewing of senior executives in the pharmaceuticals sector across four geographies: U.S., U.K., Continental Europe, and Asia Pacific.
In particular, the report analyzes the principal business issues faced by pharmaceutical firms and the operational transformation initiatives planned in response to these issues by function and by technology.
It then addresses the extent to which BPS vendors will be involved in operations transformation, together with the key vendor characteristics sought in an operations transformation partner.
Who is this Report for:
NelsonHall’s “Operational Transformation in the Pharmaceuticals Sector: 2019” report is a comprehensive market assessment report designed for:
- Sourcing managers investigating operational transformation developments within the pharmaceuticals sector
- Vendor marketing, sales and business managers developing strategies to target operational transformation and business process services (BPS) opportunities within the pharmaceuticals sector
- Financial analysts and investors specializing in the IT services and BPS sector.
Scope of this Report:
The report is based on interviews with executives in the pharmaceuticals sector in the U.S., U.K., Continental Europe, and Asia Pacific.
The report analyzes the worldwide market for operational transformation and business process services within the pharmaceuticals sector and addresses the following questions:
- What are the principal business priorities faced by organizations in the pharmaceuticals sector?
- What benefits are sought from operational transformation by pharmaceuticals firms?
- In which functional areas are pharmaceuticals firms planning operations transformation initiatives?
- What initiatives are pharmaceuticals firms planning around key technologies such as analytics, AI, and blockchain?
- To what extent, and how, will BPS vendors be involved in operations transformation?
- What are the key characteristics sought in an operations transformation partner by pharmaceutical firms?
- What levels of productivity gain are being targeted by pharmaceuticals firms?
Key Findings & Highlights:
The pharmaceuticals sector continually needs to maximize the return on its R&D, which involves identifying new uses and new geographic markets for existing drugs while speeding up R&D and reducing the time to market for new drugs. A key element here is increasing the accuracy and reducing timescales in clinical trials and adverse event reporting.
At the same time, despite their high emphasis on R&D and new drug development, it is important for pharmaceutical companies to reduce their administrative workloads, costs, and complexities. Overall, eighty-seven percent of pharmaceutical firms regard operational transformation as highly relevant to their future strategy, with:
Sourcing & procurement, as well as R&D, a key area for operational transformation within the pharmaceuticals sector
Machine learning and analytics key to transformation of drug discovery processes
Seventy-two percent of pharmaceutical firms prepared to consider operations transfer to achieve end-to-end operational synergy.